RT-1 Treatment results of salvage gamma knife stereotactic radiosurgery and bevacizumab (AVAgamma therapy) for recurrent malignant glioma

Purpose: We report the treatment results of AVAgamma therapy combining gamma knife (GK) and bevacizumab for recurrent malignant glioma. Subjects: From August 2013 to January 2021, 71 patients (Grade 2:8 patients, Grade3:16 patients, Grade 4:47 patients) with recurrent malignant glioma treated with AVAgamma therapy as salvage therapy at the time of relapse after initial treatment. The average age is 55.7 years, with 44 men and 27 women. The tumor volume is 150 ml or less, and KPS is 40% or more as the indication of AVAgamma therapy. When the irradiation volume of the gamma knife was 15 ml or less, the marginal dose was 20 to 26 Gy, and when the irradiation volume was 15 ml or more, the marginal dose was 12 to 15 Gy in two divided doses.The mean therapeutic borderline dose was 24 Gy. Bevacizumab was administered 10 mg / kg or 15 mg / kg 1 to 10 times after GK. Methods: Median progression-free survival (mPFS) from AVAgamma treatment, median survival (mOS), and mOS from initial treatment were examined and compared with mOS in the RPA classification of recurrent glioma. Results: In relapsing glioma RPA classification, NABTT CNC class 2 mOS is 17.2 months, class 3 mOS is 3.8 months, class 5 mOS is 5.6 months, class 6 mOS is 6.4 months, but mOS from AVAgamma therapy is 18 months in class 3, 11 months in class 5, 9 months in class 6. The survival time has been extended in class3, class5, class6. Discussion: By AVAgamma therapy, it was thought that recurrent lesions were locally controlled and life prognosis was prolonged. Conclusion: AVAgamma therapy is thought to prolong the survival of recurrent malignant glioma and play an important role as salvage treatment.

RT-01 Treatment results of salvage gamma knife and bevacizumab (AVAgamma therapy) for recurrent glioblastoma

Purpose: We report the treatment results of AVAgamma therapy combining gamma knife (GK) and bevacizumab for recurrent glioblastoma. Subjects: From August 2013 to April 2020, 44 patients (88 lesions) with recurrent glioblastoma treated with AVAgamma therapy as salvage therapy at the time of relapse after initial treatment. The average age is 61.5 years, with 26 men and 18 women. The tumor volume is 150 ml or less, and KPS is 40% or more as the indication of AVAgamma therapy. When the irradiation volume of GK is 15 ml or less, a single irradiation with a boundary dose of 20 to 26 Gy was performed, and when the irradiation volume was 15 ml or more, a single irradiation boundary dose was divided into two divided irradiations of 12 to 15 Gy. The mean therapeutic borderline dose was 24 Gy. Bevacizumab was administered 10 mg / kg or 15 mg / kg 1 to 10 times after GK. Methods: Median progression-free survival (mPFS), 6-month progression-free survival (PFS-6m), 6-month survival (OS-6m), median survival (mOS) from treatment with AVAgamma Considered mOS from initial treatment. Results: The mPFS from AVAgamma therapy was 5 months, PFS-6m was 37%, OS-6m was 79%, and mOS was 9 months. The mOS from initial treatment were 25 months. In relapsing glioma RPA classification, NABTT CNC class 5 mOS is 5.6 months, class 6 mOS is 6.4 months, but mOS from AVAgamma therapy is 9 months in class 5, 9 months in class 6. The survival time has been extended. Discussion: By AVAgamma therapy, it was thought that recurrent lesions were locally controlled and life prognosis was prolonged. Conclusion: AVAgamma therapy is thought to prolong the survival of recurrent glioblastoma and play an important role as salvage treatment.

Radiation hardness studies and detector characterisation at the JSI TRIGA reactor

The JSI TRIGA reactor features several in-core and ex-core irradiation facilities, each having different properties, such as neutron/gamma flux intensity, spectra and irradiation volume. A series of experiments and calculations was performed in order to characterise radiation fields in irradiation channel thus allowing users to perform irradiations in a well characterised environment. Since 2001 the reactor has been heavily used for radiation hardness studies for components used at accelerators such as the Large Hadron Collider (LHC) at CERN. Since 2010 it has been extensively used for testing of new detectors and innovative data acquisition systems and methods developed and used by the CEA. Recently, several campaigns were initiated to characterise the gamma field in the reactor and use the experimental data for improvement of the treatment of delayed gammas in Monte Carlo particle transport codes. In the future it is planned to extend the testing options by employing pulse mode operation, installation of a high energy gamma ray irradiation facility and allow irradiation of larger samples at elevated temperature.

Solvent Effects in Highly Efficient Light-Induced Molecular Aggregation

It has been reported that when irradiated with laser light non-resonant with the main absorption peaks, porphyrin molecules (4-[10,15,20-tris(4-sulfophenyl)-21,24-dihydroporphyrin-5-yl]benzenesulfonic acid, TPPS) in an aqueous solution become 10,000 to 100,000 times more efficient in light-induced molecular aggregation than expected from the ratio of gradient force potential to the thermal energy of molecules at room temperature. To determine the mechanism of this phenomenon, experiments on the light-induced aggregation of TPPS in alcohol solutions (methanol, ethanol, and butanol) were performed. In these alcohol solutions, the absorbance change was orders of magnitude smaller than in the aqueous solution. Furthermore, it was found that the absorbance change in the aqueous solution tended to be saturated with the increase of the irradiation intensity, but in the ethanol solution, the absorbance change increased linearly. These results can be qualitatively explained by the model in which intermolecular light-induced interactions between molecules within a close distance among randomly distributed molecules in the laser irradiation volume are highly relevant to the signal intensity. However, conventional dipole–dipole interactions, such as the Keesom interaction, are not quantitatively consistent with the results.

RT-01 TREATMENT RESULTS OF SALVAGE GAMMA KNIFE STEREOTACTIC RADIOSURGERY AND BEVACIZUMAB (AVAGAMMA THERAPY) FOR RECURRENT GLIOBLASTOMA

PURPOSE We report the treatment results of AVAgamma therapy combining gamma knife (GK) and bevacizumab for recurrent glioblastoma. SUBJECTS From August 2013 to April 2018, 42 patients (183 lesions) with recurrent glioblastoma treated with AVAgamma therapy as salvage therapy at the time of relapse after initial treatment. The average age is 61.1 years, with 25 men and 17 women. The tumor volume is 100 ml or less, and KPS is 40% or more as the indication of AVAgamma therapy. When the irradiation volume of GK is 15 ml or less, a single irradiation with a boundary dose of 20 Gy was performed, and when the irradiation volume was 15 ml or more, a single irradiation boundary dose was divided into two divided irradiations of 12 to 15 Gy. The mean therapeutic borderline dose was 24 Gy. Bevacizumab was administered 10 mg / kg or 15 mg / kg 1 to 10 times after GK. METHODS Median progression-free survival (mPFS), 6-month progression-free survival (PFS-6m), 6-month survival (OS-6m), median survival (mOS) from treatment with AVAgamma Considered mOS from initial treatment. [Results]: The mPFS from AVAgamma therapy was 5 months, PFS-6m was 37%, OS-6m was 84%, and mOS was 9 months. The mOS from initial treatment were 25 months. In relapsing glioma RPA classification, NABTT CNC class 5 mOS is 5.6 months, class 6 mOS is 6.4 months, but mOS from AVAgamma therapy is 9 months in class 5, 9 months in class 6. The survival time has been extended. DISCUSSION By AVAgamma therapy, it was thought that recurrent lesions were locally controlled and life prognosis was prolonged. CONCLUSION AVAgamma therapy is thought to prolong the survival of recurrent glioblastoma and play an important role as salvage treatment.

CLINICAL FEATURES AND EFFICACY OF RADIOTHERAPY FOR BONE METASTASES OF UNKNOWN ORIGIN

Purpose: to study the efficiency of radiotherapy for bone metastases of unknown origin. Material and methods: Of 686 cases of bone metastases included in the long-term randomized trial in 16 (2,4%) it was impossible to identify the primary tumor site. The most frequent primary site was breast - 62,1%, prostate and lung cancer were diagnosed in 8,3%, renal cancer in 6,9%, colon cancer in 2,6%. Separately we analyzed the mixed group of 19 patients represented by rare cases of bone metastases of stomach and liver cancer, head and neck tumors, gynecological tumors («Others»). Patient selection criteria for radiotherapy were pain, risk of pathological fracture/malignant spinal cord compression, increasing neurologic dysfunction. Irradiation volume included one anatomical area of the skeleton. Total dose was 13-26Gy in 2-4 fractions of 6,5 Gy. Results: The average follow-up period was 70 months. The main characteristics of bone metastases of unknown origin such as gender, age, lesion length, risk of pathological fracture, pain intensity before treatment and effectiveness of EBRT were similar to the bone metastases of colon cancer and to the group «Others»...